# AI Biologist - Cell Therapy Discovery at LatchBio

LatchBio is hiring an AI Biologist - Cell Therapy Discovery for a remote role open to applicants in United States. It pays $140k-$180k a year and Level rates it Works on AI ●●●○; you can [apply on LatchBio](https://jobsbylevel.com/go/bb9f4b19-1613-4a5c-a773-4dad7998058c?utm_medium=ai-agent).

AI Level 3, AI centrality 75 out of 100. Remote (San Francisco (preferred)).

## Details

- Company: [LatchBio](https://jobsbylevel.com/companies/latchbio)
- AI level: AI Level 3 (score 75 out of 100)
- Location: Remote (San Francisco (preferred))
- Salary: $140k-$180k
- Posted: November 16, 2026
- Apply: https://jobsbylevel.com/go/bb9f4b19-1613-4a5c-a773-4dad7998058c?utm_medium=ai-agent
- Free CV review for this job: https://jobsbylevel.com/cv-review?job=ai-biologist-cell-therapy-discovery-at-latchbio-5e3fa2

## Prepare for this job

The job page lists 5 likely interview questions for this offer, with a CV checklist: https://jobsbylevel.com/jobs/ai-biologist-cell-therapy-discovery-at-latchbio-5e3fa2

## Description

Latch builds rigorous scientific benchmarks ( benchmarks.bio ) for AI agents across biology. We work with frontier labs and pharma to measure whether agents can handle real biological workflows: the messy, multi-layer reasoning that matters in the field. We're seeking an AI Biologist to join our Cell Therapy Discovery team, pushing what AI can achieve in engineered cell design. About the Role You will be the scientific authority on ground truth, testing whether agents can reason like an expert cell therapy scientist. The data misleads constantly: killing is not persistence, a marker is not a phenotype, and an apparent potency difference is often just a difference in how much receptor is on the cell. Knowing what the evidence actually supports is the work. You will build the tasks and datasets behind our benchmarks across CAR, TCR, and other engineered cell formats, from antigen selection to candidate nomination. Build the task Write gold-standard answers with the rationale an experienced cell therapy scientist would defend. Design scenarios across the discovery arc: antigen prioritization, receptor and construct design, phenotype, potency and killing, cytokine profiling, exhaustion and persistence, on-target off-tumor triage. Curate datasets from real programs: multiparameter flow and spectral panels, luciferase, impedance, and imaging cytotoxicity across E:T ratios, cytokine multiplex, repeat-stimulation and serial-killing assays, inhibitory receptor panels, memory phenotype distributions, normal-tissue antigen expression. Build analysis pipelines in Python where useful, with tolerances that hold across donors, runs, and readout platforms. Set the hard calls Catch the artifact. A construct that looks weak because its surface expression is 20 percent rather than 90 percent. An E:T at saturation that erases a real potency difference visible only at lower ratios. A viability readout depressed because dead effectors overlay the targets at high E:T. Activation-induced cell death confounding a long co-culture. Lysis not normalized to the matched untransduced control at the same E:T. Donor variation read as a construct effect. Spillover error in a dim inhibitory-receptor channel. Separate activation from exhaustion. PD-1, CD69, and CD25 rise transiently on recently activated effectors and prove nothing alone. Stable exhaustion needs sustained or repeated stimulation, multiple co-expressed inhibitory receptors, and functional loss. Test whether agents know which timepoint and evidence the claim requires. Recognize tonic signaling. Antigen-independent activation from scFv instability and self-aggregation, or from hinge, transmembrane, and costimulatory domain choice, drives early differentiation and exhaustion with no antigen present. Higher affinity can raise antigen-specific and tonic signaling together. Test whether agents reach for the construct explanation instead of calling it biology. Adjudicate conflicts. Strong short-term killing against poor persistence. Low cytokine output as a design choice or a failing product. Then name the experiment that settles it. Weigh the tradeoffs. Potency versus exhaustion, cytokine output versus toxicity risk, affinity versus on-target off-tumor selectivity, and when an expansion gain costs a memory phenotype. Judge the agent Interrogate reasoning step by step, and challenge conclusions that would not survive a project review. Pinpoint where agents go wrong: why the step fails, what an expert would do, what evidence would change the call. Score confidence, rewarding explicit uncertainty over overconfident calls on ambiguous data. Requirements PhD in immunology, cell biology, bioengineering, or a related field. An MS with equivalent hands-on program experience also qualifies. 2 to 6 years hands-on in cell therapy at a biotech or pharma, with your own analysis work in the last two years. You have personally generated or analyzed data that decided which target or construct advanced, and you can

The description is cut here. Read the full offer: https://jobsbylevel.com/jobs/ai-biologist-cell-therapy-discovery-at-latchbio-5e3fa2

Source: https://jobsbylevel.com/jobs/ai-biologist-cell-therapy-discovery-at-latchbio-5e3fa2

## Cite this page

Level. https://jobsbylevel.com/jobs/ai-biologist-cell-therapy-discovery-at-latchbio-5e3fa2.

Get job alerts: https://jobsbylevel.com/newsletter
